<li>5-htp<p>fluoxetine and 5-htp both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>abiraterone<p>abiraterone increases levels of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>aceclofenac<p>fluoxetine, aceclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>acemetacin<p>fluoxetine, acemetacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>albuterol<p>fluoxetine and albuterol both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>alfuzosin<p>alfuzosin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>almotriptan<p>almotriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>alosetron<p>fluoxetine will increase the level or effect of alosetron by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>amisulpride<p>amisulpride and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amitriptyline<p>amitriptyline and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amoxapine<p>amoxapine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amphetamine<p>amphetamine increases toxicity of fluoxetine by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>apomorphine<p>apomorphine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>arformoterol<p>arformoterol and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>artemether/lumefantrine<p>fluoxetine and artemether/lumefantrine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>asenapine<p>asenapine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>asenapine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>aspirin<p>fluoxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin rectal<p>fluoxetine, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>fluoxetine, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>atomoxetine<p>fluoxetine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.</p></li><li>axitinib<p>fluoxetine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bedaquiline<p>fluoxetine and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely</p></li><li>bosentan<p>fluoxetine will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>brexpiprazole<p>fluoxetine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. If also administered with a strong/moderate CYP3A4 inhibitor, administer a quarter of brexpiprazole dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD.</p></li><li>buprenorphine subdermal implant<p>fluoxetine, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>bupropion<p>bupropion will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>carbamazepine<p>fluoxetine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor plasma levels when used concomitantly</p></li><li>carvedilol<p>fluoxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>fluoxetine will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>celecoxib will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>chlorpromazine<p>chlorpromazine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>chlorpropamide<p>fluoxetine increases effects of chlorpropamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>choline magnesium trisalicylate<p>fluoxetine, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>cilostazol<p>fluoxetine increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase  serum levels of 3,4-dehydrocilostazol (active metabolite).</p></li><li>cimetidine<p>cimetidine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>ciprofloxacin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>citalopram<p>citalopram and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clarithromycin<p>clarithromycin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clobazam<p>clobazam will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. </p></li><li>clomipramine<p>clomipramine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clopidogrel<p>fluoxetine increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration of SSRIs with clopidogrel may increase the risk of bleeding.</p></li><li>clozapine<p>fluoxetine increases levels of clozapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .<span><br><br></span>clozapine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>cocaine<p>fluoxetine and cocaine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>codeine<p>fluoxetine will decrease the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine</p></li><li>crizotinib<p>crizotinib and fluoxetine both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>cyproheptadine<p>fluoxetine increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>dasatinib<p>dasatinib and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>defibrotide<p>defibrotide increases effects of fluoxetine by Other (see comment). Use Caution/Monitor. 
Comment: Defibrotide may enhance effects of platelet inhibitors.</p></li><li>desipramine<p>desipramine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dexfenfluramine<p>fluoxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dextroamphetamine<p>fluoxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and dextroamphetamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>diazepam<p>fluoxetine will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and fluoxetine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>fluoxetine will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>diflunisal<p>fluoxetine, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>dihydroergotamine<p>fluoxetine and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dihydroergotamine intranasal<p>fluoxetine and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dofetilide<p>dofetilide and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dolasetron<p>dolasetron and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>donepezil<p>fluoxetine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>doxepin<p>doxepin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dronedarone<p>dronedarone and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>droperidol<p>droperidol and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>eletriptan<p>eletriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>eliglustat<p>eliglustat increases levels of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>eluxadoline<p>fluoxetine increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of fluoxetine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>encainide<p>fluoxetine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>epinephrine<p>epinephrine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>epinephrine racemic<p>epinephrine racemic and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ergotamine<p>fluoxetine and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>erythromycin base<p>erythromycin base and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin stearate<p>erythromycin stearate and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>escitalopram<p>escitalopram and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ethotoin<p>fluoxetine will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>etodolac<p>fluoxetine, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etoricoxib<p>fluoxetine, etoricoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etravirine<p>fluoxetine will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ezogabine<p>ezogabine and fluoxetine both increase  QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.</p></li><li>fenbufen<p>fluoxetine, fenbufen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenfluramine<p>fluoxetine and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>fluoxetine, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fesoterodine<p>fluoxetine will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>flecainide<p>flecainide and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>flibanserin<p>fluoxetine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fluconazole<p>fluconazole and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>flurbiprofen<p>fluoxetine will increase the level or effect of flurbiprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fluvastatin<p>fluoxetine will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluoxetine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and fluvoxamine both increase  QTc interval. Use Caution/Monitor.</p></li><li>formoterol<p>fluoxetine and formoterol both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>foscarnet<p>fluoxetine and foscarnet both increase  QTc interval. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fluoxetine will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>frovatriptan<p>frovatriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>galantamine<p>fluoxetine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>gemifloxacin<p>gemifloxacin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>glimepiride<p>fluoxetine increases effects of glimepiride by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glipizide<p>fluoxetine increases effects of glipizide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>gliquidone<p>fluoxetine increases effects of gliquidone by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glyburide<p>fluoxetine increases effects of glyburide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>green tea<p>green tea, fluoxetine. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>haloperidol<p>fluoxetine and haloperidol both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>hydrocodone<p>hydrocodone increases effects of fluoxetine by serotonin levels. Use Caution/Monitor. Serotonin syndrome may occur.</p></li><li>ibuprofen<p>fluoxetine will increase the level or effect of ibuprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>iloperidone<p>fluoxetine and iloperidone both increase  QTc interval. Use Caution/Monitor.</p></li><li>imatinib<p>imatinib will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>imipramine<p>imipramine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>indacaterol, inhaled<p>indacaterol, inhaled and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>indomethacin<p>fluoxetine, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>insulin degludec<p>fluoxetine, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin degludec/insulin aspart<p>fluoxetine, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin inhaled<p>fluoxetine, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>isoniazid<p>fluoxetine and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>itraconazole<p>fluoxetine and itraconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ivacaftor<p>fluoxetine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .</p></li><li>ketoconazole<p>fluoxetine and ketoconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ketoprofen<p>fluoxetine, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac<p>fluoxetine, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac intranasal<p>fluoxetine, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>l-tryptophan<p>fluoxetine and l-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lamotrigine<p>lamotrigine increases toxicity of fluoxetine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychomotor impairment may be enhanced.</p></li><li>lapatinib<p>fluoxetine and lapatinib both increase  QTc interval. Use Caution/Monitor.</p></li><li>lenvatinib<p>fluoxetine and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.</p></li><li>levalbuterol<p>fluoxetine and levalbuterol both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>levofloxacin<p>fluoxetine and levofloxacin both increase  QTc interval. Use Caution/Monitor.</p></li><li>lisdexamfetamine<p>fluoxetine and lisdexamfetamine both increase  serotonin levels. Use Caution/Monitor.</p></li><li>lithium<p>fluoxetine and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lomitapide<p>fluoxetine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>loratadine<p>fluoxetine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>fluoxetine, lornoxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>losartan<p>fluoxetine will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>lsd<p>fluoxetine and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, fluoxetine. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>lumefantrine<p>fluoxetine and lumefantrine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lurasidone<p>lurasidone, fluoxetine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maprotiline<p>maprotiline and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>meclofenamate<p>fluoxetine, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mefenamic acid<p>fluoxetine, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>meloxicam<p>fluoxetine will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>methadone<p>fluoxetine and methadone both increase  QTc interval. Use Caution/Monitor.</p></li><li>mianserin<p>mianserin and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>mifepristone<p>mifepristone, fluoxetine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.</p></li><li>mipomersen<p>mipomersen, fluoxetine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>fluoxetine and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>morphine<p>fluoxetine and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>moxifloxacin<p>fluoxetine and moxifloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>fluoxetine, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naproxen<p>fluoxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naratriptan<p>naratriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nateglinide<p>fluoxetine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>nifedipine<p>fluoxetine will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider initiating nifedipine at the lowest dose available if given concomitantly with this medication</p></li><li>nilotinib<p>fluoxetine and nilotinib both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>nortriptyline<p>nortriptyline and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide<p>fluoxetine and octreotide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide (antidote)<p>fluoxetine and octreotide (antidote) both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ofloxacin<p>fluoxetine and ofloxacin both increase  QTc interval. Use Caution/Monitor.</p></li><li>olodaterol inhaled<p>fluoxetine and olodaterol inhaled both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>osimertinib<p>osimertinib and fluoxetine both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.</p></li><li>oxaprozin<p>fluoxetine, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>paliperidone<p>fluoxetine and paliperidone both increase  QTc interval. Use Caution/Monitor.</p></li><li>parecoxib<p>fluoxetine will increase the level or effect of parecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, parecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>paroxetine<p>fluoxetine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>pasireotide<p>fluoxetine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, fluoxetine. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>fluoxetine and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>pentoxifylline<p>pentoxifylline increases toxicity of fluoxetine by anticoagulation. Use Caution/Monitor. May increase bleeding.</p></li><li>perhexiline<p>fluoxetine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>phenytoin<p>fluoxetine will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>pirbuterol<p>fluoxetine and pirbuterol both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>piroxicam<p>fluoxetine will increase the level or effect of piroxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>posaconazole<p>fluoxetine and posaconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>prochlorperazine<p>fluoxetine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>prochlorperazine and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>promazine<p>fluoxetine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>promazine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>promethazine<p>promethazine and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>protriptyline<p>protriptyline and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>quetiapine<p>quetiapine, fluoxetine.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.</p></li><li>quinine<p>fluoxetine and quinine both increase  QTc interval. Use Caution/Monitor.</p></li><li>ramelteon<p>fluoxetine will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ranolazine<p>fluoxetine and ranolazine both increase  QTc interval. Use Caution/Monitor.</p></li><li>rilpivirine<p>rilpivirine increases toxicity of fluoxetine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.</p></li><li>risperidone<p>fluoxetine and risperidone both increase  QTc interval. Use Caution/Monitor.</p></li><li>rizatriptan<p>rizatriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>romidepsin<p>fluoxetine and romidepsin both increase  QTc interval. Use Caution/Monitor.</p></li><li>safinamide<p>fluoxetine, safinamide.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor patients for symptoms of serotonin syndrome if SSRIs are coadministered with safinamide.</p></li><li>salicylates (non-asa)<p>fluoxetine, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>salmeterol<p>fluoxetine and salmeterol both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>salsalate<p>fluoxetine, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>same<p>fluoxetine and same both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>saquinavir<p>saquinavir and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sertindole<p>fluoxetine and sertindole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sertraline<p>sertraline and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>fluoxetine, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>fluoxetine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sorafenib<p>sorafenib and fluoxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>fluoxetine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>sulfasalazine<p>fluoxetine, sulfasalazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sulindac<p>fluoxetine, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sumatriptan<p>sumatriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan intranasal<p>sumatriptan intranasal and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan transdermal<p>sumatriptan transdermal and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sunitinib<p>sunitinib and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tamoxifen<p>fluoxetine will decrease the level or effect of tamoxifen by  decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.</p></li><li>tamsulosin<p>fluoxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tapentadol<p>fluoxetine and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telavancin<p>fluoxetine and telavancin both increase  QTc interval. Use Caution/Monitor.</p></li><li>telithromycin<p>fluoxetine and telithromycin both increase  QTc interval. Use Caution/Monitor.</p></li><li>terbutaline<p>fluoxetine and terbutaline both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>tetrabenazine<p>fluoxetine increases effects of tetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decrease tetrabenazine dose by 50% when coadministered with strong CYP2D6 inhibitors.</p></li><li>thiothixene<p>thiothixene and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tolazamide<p>fluoxetine increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolbutamide<p>fluoxetine will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine increases effects of tolbutamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolfenamic acid<p>fluoxetine, tolfenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tolmetin<p>fluoxetine, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>toremifene<p>toremifene and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tramadol<p>fluoxetine and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>trazodone<p>trazodone and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trifluoperazine<p>fluoxetine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>trifluoperazine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>fluoxetine and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>trimipramine<p>trimipramine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tropisetron<p>fluoxetine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and tropisetron both increase  QTc interval. Use Caution/Monitor.</p></li><li>umeclidinium bromide/vilanterol inhaled<p>fluoxetine and umeclidinium bromide/vilanterol inhaled both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>valerian<p>valerian and fluoxetine both increase  sedation. Use Caution/Monitor.</p></li><li>vardenafil<p>vardenafil and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>venlafaxine<p>fluoxetine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>vilanterol/fluticasone furoate inhaled<p>fluoxetine and vilanterol/fluticasone furoate inhaled both increase  QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular system</p></li><li>vorapaxar<p>fluoxetine, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>voriconazole<p>fluoxetine will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and voriconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>vorinostat<p>vorinostat and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>warfarin<p>fluoxetine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ziprasidone<p>fluoxetine and ziprasidone both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>zolmitriptan<p>zolmitriptan and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>zotepine<p>fluoxetine increases levels of zotepine by decreasing metabolism. Use Caution/Monitor.</p></li>